Preferred Label : MVA-BN-Brachyury-TRICOM Vaccine;
NCIt synonyms : MVA-BN-Brachyury; MVA-BN-Brachyury Prime Vaccine;
NCIt definition : A cancer priming vaccine consisting of a proprietary version of the recombinant vaccinia
viral vector, modified vaccinia Ankara-Bavarian Nordic (MVA-BN), encoding the human
transcription factor and tumor-associated antigen (TAA) brachyury, and a triad of
T-cell co-stimulatory molecules (TRICOM), which is comprised of the three human immune-enhancing
co-stimulatory molecules B7-1, ICAM-1 and LFA-3, with potential immunostimulatory
and antineoplastic activities. Upon subcutaneous administration of MVA-BN-brachyury
vaccine, the vector expresses the brachyury protein. The expressed brachyury protein
may induce a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells
expressing brachyury. The MVA-BN-brachyury vaccine, which is a priming vaccine, is
followed by multiple boosting doses of the fowlpox virus (FPV)-brachyury vaccine.
The expression of brachyury, a member of the T-box family of transcription factors
that is overexpressed in numerous cancer cell types, is correlated with increased
epithelial-mesenchymal transition (EMT), cancer resistance, cancer progression and
metastasis. TRICOM enhances antigen-specific T-cell activation.;
UNII : GD1ZWN2I2Y;
NCI Metathesaurus CUI : CL551009;
Origin ID : C148400;
UMLS CUI : C4727626;
Semantic type(s)
- chemical_or_drug_affects_cell_type_or_tissue
- chemical_or_drug_has_mechanism_of_action
- chemical_or_drug_has_physiologic_effect
- concept_is_in_subset
- has_target
